RecruitingPhase 2Phase 3NCT07462143

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

A Randomized, Multicenter, Phase Ⅱ/Ⅲ Study of RC148 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy as First-line Treatment for Unresectable or Metastatic Colorectal Cancer

Sponsor

RemeGen Co., Ltd.

Enrollment

80 participants

Start Date

May 12, 2026

Study Type

INTERVENTIONAL

Conditions

Colorectal (Colon or Rectal) Cancer

Summary

This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called RC148 (Dose 1) plus Capecitabine and Oxaliplatin and a drug called RC148 (Dose 2) plus Capecitabine and Oxaliplatin for people with colorectal (colon or rectal) cancer. The study is currently recruiting participants at 19 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRC148 (Dose 1) plus Capecitabine and Oxaliplatin

RC148 (Dose 1) plus Capecitabine and Oxaliplatin

DRUGRC148 (Dose 2) plus Capecitabine and Oxaliplatin

RC148 (Dose 2) plus Capecitabine and Oxaliplatin

Locations(19)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

Meizhou People's Hospital

Meizhou, Guangdong, China

Guangxi Medical University Cancer Hospital

Nanjing, Guangxi, China

The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital

Shijiazhuang, Hebei, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Tongji Medical College of Huazhong University of Science &Technology

Wuhan, Hubei, China

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

Jiangsu Cancer Hospital

Nanjing, Jiangsu, China

Affiliated Hospital of Jiangnan University

Wuxi, Jiangsu, China

The first hospital of Jilin University

Changchun, Jilin, China

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Shanxi Cancer Hospital

Taiyuan, Shanxi, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

People's Hospital of Tianjin

Tianjin, Tianjin Municipality, China

Yunnan Cancer Hospital

Kunming, Yunnan, China

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07462143

Related Trials

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

NCT075298081 location

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

NCT076759671 location

Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy

NCT074194901 location

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

NCT073211068 locations

Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)

NCT073611071 location